NEW AVENUES IN ANTIHYPERTENSIVE DRUG-TREATMENT

被引:4
作者
VANZWIETEN, PA [1 ]
机构
[1] UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOL, 1105 AZ AMSTERDAM, NETHERLANDS
基金
英国医学研究理事会;
关键词
ANTIHYPERTENSIVE DRUGS; ANGIOTENSIN II-RECEPTOR ANTAGONISTS; IMIDAZOLINE RECEPTOR AGONISTS; ENDOPEPTIDASE INHIBITORS; HYBRID ANTIHYPERTENSIVE DRUGS;
D O I
10.3109/10641969309037106
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
After a brief synopsis Of the classical antihypertensive drugs a survey is given of the newer therapeutics, such as calcium antagonists, ACE-inhibitors and alpha1-adrenoceptor antagonists. Experimental drugs, such as imidazoline receptor agonists, renin inhibitors, angiotensin II receptor antagonists, alpha2-adrenoceptor antagonists, potassium channel openers, ketanserin, endopeptidase inhibitors, and hybrid (multifactorial) drugs are discussed, with special attention for their modes of action. In spite of the ever increasing number of antihypertensive drugs and principles, the large scale of clinical evidence for a beneficial effect of long-term treatment (in particular with respect to protection against stroke) remains limited to diuretics and beta-blockers. In spite of this limitation it seems worthwhile to consider the newer antihypertensive drugs as well, especially for optimal treatment of the individual patient. The newer drugs may in particular offer special advantages in the presence of concomitant diseases, such as diabetes mellitus, hyperlipidaemia, angina pectoris or congestive heart failure.
引用
收藏
页码:1205 / 1220
页数:16
相关论文
共 36 条